Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Senzer

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Current Pharmaceutical Biotechnology|July 12, 2011
Oncolytic viruses for induction of anti-tumor immunityAlex W Tong, Neil Senzer, Vincenzo Cerullo, et al.
Seminars in Radiation Oncology|March 28, 2002
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiationMatthew Arquette, Todd Wasserman, Ramaswamy Govindan, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 3, 2012
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical applicationDonald D Rao, Neil Senzer, Zhaohui Wang, et al.
International Journal of General Medicine|March 16, 2011
Procoagulant inhibitory properties of paclitaxel poliglumexJohn Nemunaitis, Neil Senzer, Barry Cooper, et al.
Cancer Investigation|December 27, 2005
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumorsJohn Nemunaitis, Casey Cunningham, Neil Senzer, et al.
The Journal of Oncology Management : the Official Journal of the American College of Oncology Administrators|September 16, 2005
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patientsJohn Nemunaitis, Ned Adams, Casey Cunningham, et al.
Clinical Colorectal Cancer|March 16, 2016
A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal CancerNeil H Segal, Purvi Gada, Neil Senzer, et al.
Gastrointestinal Endoscopy|April 24, 2012
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancerKenneth J Chang, Tony Reid, Neil Senzer, et al.
Future Science OA|March 26, 2019
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapyAli Alqahtani, Khalil Choucair, Mushtaq Ashraf, et al.
Annals of Surgical Oncology|September 1, 2005
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-upJames M McLoughlin, Todd M McCarty, Casey Cunningham, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Current Pharmaceutical Biotechnology|July 12, 2011
Oncolytic viruses for induction of anti-tumor immunityAlex W Tong, Neil Senzer, Vincenzo Cerullo, et al.
Seminars in Radiation Oncology|March 28, 2002
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiationMatthew Arquette, Todd Wasserman, Ramaswamy Govindan, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 3, 2012
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical applicationDonald D Rao, Neil Senzer, Zhaohui Wang, et al.
International Journal of General Medicine|March 16, 2011
Procoagulant inhibitory properties of paclitaxel poliglumexJohn Nemunaitis, Neil Senzer, Barry Cooper, et al.
Cancer Investigation|December 27, 2005
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumorsJohn Nemunaitis, Casey Cunningham, Neil Senzer, et al.
The Journal of Oncology Management : the Official Journal of the American College of Oncology Administrators|September 16, 2005
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patientsJohn Nemunaitis, Ned Adams, Casey Cunningham, et al.
Clinical Colorectal Cancer|March 16, 2016
A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal CancerNeil H Segal, Purvi Gada, Neil Senzer, et al.
Gastrointestinal Endoscopy|April 24, 2012
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancerKenneth J Chang, Tony Reid, Neil Senzer, et al.
Future Science OA|March 26, 2019
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapyAli Alqahtani, Khalil Choucair, Mushtaq Ashraf, et al.
Annals of Surgical Oncology|September 1, 2005
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-upJames M McLoughlin, Todd M McCarty, Casey Cunningham, et al.
Pageof 8